Publicaciones destacadas

  • Hepatocellular carcinoma

    Autores: Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS.
    Referencia: Nature Reviews Disease Primers 2021; 7(1):6-.
  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Autores: Pfister, Dominik; Nunez, Nicolas Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Mueller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Dudek, Michael; Yousuf, Suhail; Inverso, Donato; Singh, Indrabahadur; Teijeiro, Ana; Castet, Florian; Montironi, Carla; Haber, Philipp K.; Tiniakos, Dina; Bedossa, Pierre; Cockell, Simon; Younes, Ramy; Vacca, Michele; Marra, Fabio; Schattenberg, Jorn M.; Allison, Michael; Bugianesi, Elisabetta; Ratziu, Vlad; Pressiani, Tiziana; D'Alessio, Antonio; Personeni, Nicola; Rimassa, Lorenza; Daly, Ann K.; Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M.; Vogel, Arndt; Peck-Radosavljevic, Markus; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Trojan, Jorg; Schulze, Kornelius; Wege, Henning; Koch, Sandra; Weinmann, Arndt; Bueter, Marco; Rossler, Fabian; Siebenhuner, Alexander; De Dosso, Sara; Mallm, Jan-Philipp; Umansky, Viktor; Jugold, Manfred; Luedde, Tom; Schietinger, Andrea; Schirmacher, Peter; Emu, Brinda; Augustin, Hellmut G.; Billeter, Adrian; Mueller-Stich, Beat; Kikuchi, Hiroto; Duda, Dan G.; Kutting, Fabian; Waldschmidt, Dirk-Thomas; Ebert, Matthias Philip; Rahbari, Nuh; Mei, Henrik E.; Schulz, Axel Ronald; Ringelhan, Marc; Malek, Nisar; Spahn, Stephan; Bitzer, Michael; Ruiz de Galarreta, Marina; Lujambio, Amaia; Dufour, Jean-Francois; Marron, Thomas U.; Kaseb, Ahmed; Kudo, Masatoshi; Huang, Yi-Hsiang; Djouder, Nabil; Wolter, Katharina; Zender, Lars; Marche, Parice N.; Decaens, Thomas; Pinato, David J.; Rad, Roland; Mertens, Joachim C.; Weber, Achim; Unger, Kristian; Meissner, Felix; Roth, Susanne; Jilkova, Zuzana Macek; Claassen, Manfred; Anstee, Quentin M.; Amit, Ido; Knolle, Percy; Becher, Burkhard; Llovet, Josep M.; Heikenwalder, Mathias;.
    Referencia: Nature 2021; 592(7854):450-456.
  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Autores: Zhu, Andrew X; Kang, Yoon-Koo; Yen, Chia-Jui; Finn, Richard S; Galle, Peter R; Llovet, Josep M; Assenat, Eric; Brandi, Giovanni; Pracht, Marc; Lim, Ho Yeong; Rau, Kun-Ming; Motomura, Kenta; Ohno, Izumi; Merle, Philippe; Daniele, Bruno; Shin, Dong Bok; Gerken, Guido; Borg, Christophe; Hiriart, Jean-Baptiste; Okusaka, Takuji; Morimoto, Manabu; Hsu, Yanzhi; Abada, Paolo B; Kudo, Masatoshi;REACH-2 Study Investigators.
    Referencia: Lancet Oncology 2019; 20(2):282-296.
  • Molecular therapies and precision medicine for hepatocellular carcinoma

    Autores: Llovet J; Montal R; Sia D; Finn R.
    Referencia: Nature Reviews Clinical Oncology 2018; 15(10):599-616.
  • Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

    Autores: Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM .
    Referencia: Gastroenterology 2017; 153(3):812-826.
  • Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

    Autores: Sia, Daniela; Losic, Bojan; Moeini, Agrin; Cabellos, Laia; Hao, Ke; Revill, Kate; Bonal, Dennis; Miltiadous, Oriana; Zhang, Zhongyang; Hoshida, Yujin; Cornella, Helena; Castillo-Martin, Mireia; Pinyol, Roser; Kasai, Yumi; Roayaie, Sasan; Thung, Swan N; Fuster, Josep; Schwartz, Myron E; Waxman, Samuel; Cordon-Cardo, Carlos; Schadt, Eric; Mazzaferro, Vincenzo; Llovet, Josep M.
    Referencia: Nature Communications 2015; 6( ):6087-.
  • Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

    Autores: Schulze K., Imbeaud S., Letouzé E., Alexandrov L.B., Calderaro J., Rebouissou S., Couchy G., Meiller C., Shinde J., Soysouvanh F., Calatayud A.L., Pinyol R., Pelletier L., Balabaud C., Laurent A., Blanc J.F., Mazzaferro V., Calvo F., Villanueva A., Nault J.C., Bioulac-Sage P., Stratton M.R., Llovet J.M., Zucman-Rossi J..
    Referencia: Nature Genetics 2015; 47(5):505-U106.
  • Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes

    Autores: Sia, Daniela; Hoshida, Yujin; Villanueva, Augusto; Roayaie, Sasan; Ferrer, Joana; Tabak, Barbara; Peix, Judit; Sole, Manel; Tovar, Victoria; Alsinet, Clara; Cornella, Helena; Klotzle, Brandy; Fan, Jian-Bing; Cotsoglou, Christian; Thung, Swan N; Fuster, Josep; Waxman, Samuel; Garcia-Valdecasas, Juan Carlos; Bruix, Jordi; Schwartz, Myron E; Beroukhim, Rameen; Mazzaferro, Vincenzo; Llovet, Josep M.
    Referencia: Gastroenterology 2013; 144(4):829-840.
  • Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

    Autores: Hoshida, Yujin; Villanueva, Augusto; Kobayashi, Masahiro; Peix, Judit; Chiang, Derek Y; Camargo, Amy; Gupta, Supriya; Moore, Jamie; Wrobel, Matthew J; Lerner, Jim; Reich, Michael; Chan, Jennifer A; Glickman, Jonathan N; Ikeda, Kenji; Hashimoto, Masaji; Watanabe, Goro; Daidone, Maria G; Roayaie, Sasan; Schwartz, Myron; Thung, Swan; Salvesen, Helga B; Gabriel, Stacey; Mazzaferro, Vincenzo; Bruix, Jordi; Friedman, Scott L; Kumada, Hiromitsu; Llovet, Josep M; Golub, Todd R.
    Referencia: New England Journal Of Medicine 2008; 359(19):1995-2004.
  • Sorafenib in advanced hepatocellular carcinoma.

    Autores: Llovet Bayer, Josep M..
    Referencia: The New England Journal Of Medicine 2008; 359(4):378-390.

Proyectos destacados

  • HUNTER-Hepatocellular Carcinoma Expediter Network CRUK, AEDD, AIRC Accelerator Award.

    Investigador/a principal: Josep Mª Llovet Bayer
    Financiador: Asociación Española Contra el Cáncer (AECC) ; CRUK, AECC, AIRC Accelerator Award
    Código: AECC-Accelerator Award 2017
    Duración: 01/01/2019 - 31/12/2023
  • Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities (HEP-CAR)

    Investigador/a principal: Josep Mª Llovet Bayer
    Financiador: HORIZON 2020. Call H2020-PHC-2015 ; IDIBAPS-Hospital Clínic (Sede); Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen)
    Código: 667273
    Duración: 01/01/2016 - 31/12/2019
  • Integrative genomic analysis of intrahepatic cholangiocarcinoma (AECC_Grupo Estable 11)

    Investigador/a principal: Josep Maria Llovet Bayer
    Financiador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC)
    Código: GCA110347LLOV
    Duración: 01/09/2011 - 31/08/2018
  • Genomic predictors and oncogenic drivers in hepatocellular carcinoma (HEPTROMIC)

    Financiador: European Comission (EC)
    Código: FP7-Health-2ST-10 (259744)
    Duración: 01/11/2010 - 26/11/2014
  • Integrative genomic analysis in hepatocellular carcinoma

    Investigador/a principal: Josep M Llovet Bayer
    Código: 5R01DK076986-05
    Duración: 10/08/2007 - 31/07/2012